ReviewArchivum immunologiae et therapiae experimentalis2021
DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
Review in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Diabetes Mellitus, a Leading Comorbidity in COVID-19: an Insight on Pathophysiology, Molecular Interactions, and Comprehensive Management.Current microbiology · 2025Pooled it
- The High Levels of Soluble Receptors for Tumor Necrosis Factor and Heart Injury in Children with the Pediatric Inflammatory Multisystem Syndrome Associated with Coronavirus Infection: Is This Just a Coincidence? A Proof-of-Concept Study.International journal of molecular sciences · 2025Article
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19.Journal of pharmacy practice · 2023Review
- COVID-19 Outcomes and Diabetes Mellitus: A Comprehensive Multicenter Prospective Cohort Study.Microorganisms · 2023Article
- Changes in intestinal morphology, number of mucus-producing cells and expression of coronavirus receptors APN, DPP4, ACE2 and TMPRSS2 in pigs with aging.Veterinary research · 2023Article
- Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives mInternational journal of oncology · 2023Article
- The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs.Brain sciences · 2023Review
- Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?Inflammopharmacology · 2022Review
- Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control.World journal of virology · 2022Review
- Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Toll-like receptor 4 in COVID-19: friend or foe?Future virology · 2022Article
- SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.International journal of molecular sciences · 2022Review
- COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.Frontiers in endocrinology · 2022Review
- Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.Frontiers in endocrinology · 2022 · on this mapObservational
- Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong.Diabetes & metabolism · 2022Article
- Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2.Frontiers in immunology · 2022Review
- Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.International journal of clinical practice · 2021Review
- Genetic Insights into the Middle East Respiratory Syndrome Coronavirus Infection among Saudi People.Vaccines · 2021Article
- Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.